| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10555938 | AMRYT | Methods for treating disorders or diseases associated with hyperlipidemia and hypercholesterolemia while minimizing side effects |
Mar, 2025
(1 year, 5 months from now) | |
| US8618135 | AMRYT | Methods for treating disorders or diseases associated with hyperlipidemia and hypercholesterolemia while minimizing side effects |
Mar, 2025
(1 year, 5 months from now) | |
| US9265758 | AMRYT | Methods for treating disorders or diseases associated with hyperlipidemia and hypercholesterolemia while minimizing side-effects |
Mar, 2025
(1 year, 5 months from now) | |
| US9364470 | AMRYT | Methods for treating disorders or diseases associated with hyperlipidemia and hypercholesterolemia while minimizing side-effects |
Mar, 2025
(1 year, 5 months from now) | |
| US9433617 | AMRYT | Methods for treating disorders or diseases associated with hyperlipidemia and hypercholesterolemia while minimizing side-effects |
Mar, 2025
(1 year, 5 months from now) | |
| US9861622 | AMRYT | Methods for treating disorders or diseases associated with hyperlipidemia and hypercholesterolemia while minimizing side-effects |
Mar, 2025
(1 year, 5 months from now) | |
| US10016404 | AMRYT | Methods for treating disorders or diseases associated with hyperlipidemia and hypercholesterolemia while minimizing side effects |
Mar, 2025
(1 year, 5 months from now) | |
| US7932268 | AMRYT | Methods for treating disorders or diseases associated with hyperlipidemia and hypercholesterolemia while minimizing side effects |
Aug, 2027
(3 years from now) | |
Juxtapid is owned by Amryt.
Juxtapid contains Lomitapide Mesylate.
Juxtapid has a total of 8 drug patents out of which 0 drug patents have expired.
Juxtapid was authorised for market use on 21 December, 2012.
Juxtapid is available in capsule;oral dosage forms.
Juxtapid can be used as a dosing regimen for the treatment of hypercholesterolemia and hyperlipidemia in patients with homozygous familial hypercholesterolemia using at least three step-wise increasing doses, a dosing regimen for the treatment of hypercholesterolemia and hyperlipidemia in patients with homozygous familial hypercholesterolemia using at least three step-wise increasing doses.
The generics of Juxtapid are possible to be released after 19 August, 2027.
Drugs and Companies using LOMITAPIDE MESYLATE ingredient
Market Authorisation Date: 21 December, 2012
Treatment: A dosing regimen for the treatment of hypercholesterolemia and hyperlipidemia in patients with homozygous familial hypercholesterolemia using at least three step-wise increasing doses; A dosing regime...
Dosage: CAPSULE;ORAL
JUXTAPID family patents
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic